Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Think Research Corporation V.THNK

Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.


TSXV:THNK - Post by User

Comment by dt_coreon Feb 16, 2024 9:49am
113 Views
Post# 35883957

RE:RE:RE:RE:RE:RE:Investor relations rating

RE:RE:RE:RE:RE:RE:Investor relations ratingTo put this deal into perspective it values the entire company, including debt, at an enterprise value of $76 million. That is rock bottom low valuation (0.8x 2024 sales!). I've done the math assuming that higher bids may trigger Beedie conversion, so with that in mind a 1.0x EV/2024 Sales multiple wold imply a stock price of 0.50 cents. I would expect bidders like Well as being more than willing to pay that especially since wiping out THNKS debt unlocks almost $6M in additional cash flow. A typical premium for small cap Canadian companies like THNK is in the range of 1.5x to 2.0x EV/Sales. That would imply a share price of 0.85 to 1.25.

My expectation at this point is for a Well Health to bid somewhere between 40 and 50 cents. Also I'm sure that lots of investors are supporting the deal simply to put the company in play and see what else they can get.
<< Previous
Bullboard Posts
Next >>